Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

(2021) Niels Jongs et al.   Lancet Diabetes & Endocrinology

Renal effects of dapagliflozin in people with and without diabetes with moderate or severe renal dysfunction: prospective modeling of an ongoing clinical trial.

(2020) Karen Melissa Hallow et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Results of DAPA-HF

(2020) Pardeep S. Jhund et al.   CIRCULATION

Dapagliflozin in Patients with Chronic Kidney Disease

(2020) Hiddo J.L. Heerspink et al.   NEW ENGLAND JOURNAL OF MEDICINE

Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.

(2020) Megumi Oshima et al.   KIDNEY INTERNATIONAL

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

(2020) David C Wheeler et al.   Lancet Diabetes & Endocrinology

Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease

(2020) John J.V. McMurray et al.   CIRCULATION

Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial

(2020) Bettina J. Kraus et al.   KIDNEY INTERNATIONAL

Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials

(2019) Robert D. Toto et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials

(2019) Lesley A. Inker et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Performance of GFR Slope as a Surrogate Endpoint for Kidney Disease Progression in Clinical Trials: A Statistical Simulation

(2019) Tom Greene et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Mixed‐effects models for slope‐based endpoints in clinical trials of chronic kidney disease

(2019) Edward Vonesh et al.   STATISTICS IN MEDICINE

Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial

(2019) Carol Pollock et al.   Lancet Diabetes & Endocrinology

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

(2019) Ofri Mosenzon et al.   Lancet Diabetes & Endocrinology

Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c

(2019) Christopher P. Cannon et al.   CIRCULATION

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

(2019) Hiddo J L Heerspink et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial

(2018) Christoph Wanner et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus

(2016) Hiddo J.L. Heerspink et al.   CIRCULATION